Combined HP <sup>13</sup>C Pyruvate and <sup>13</sup>C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts.

Biomedicines · 2022 · PMC8945537 · PMID 35327519

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The p-ERK levels, assessed at 4 h post-treatment, showed a trend to a decrease in response to all treatments, in accordance with the efficacy of the targeted treatments.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.